7701 Q1 2027 Earnings Presentation

Page 1

SHIMADZU Excellence in Science FY2026 Q1 ( FYE3 / 2027 ) Financial Results Presentation Shimadzu Corporation TSE Prime Market : 7701 Managing Executive Officer Yoshiaki Maeda August 6 , 2026

Page 2

Key Messages 2 Full-Year Forecast By Segment Higher Sales and OP in Q1 Sales and OP increased year on year and exceeded our expectations. • Sales: ¥130.6B (+10% YoY), setting a new Q1 sales record for the sixth consecutive year. • OP: ¥14.3B (+17% YoY), setting a new Q1 OP record for the first time in three years. Segment OP is now disclosed as OP before amortization of goodwill and other intangible assets. • AMI: Higher Sales, Lower OP. Sales increased through value-added pricing; however, OP declined due to the situation in the Middle East. • MED: Higher Sales and OP, driven by solid sales of X-Ray Systems. • IM: Higher Sales and OP, led by robust Turbomolecular Pump (TMP) sales. • AE: Higher Sales and OP, with growth in both defense and commercial aircraft. Full-year guidance has been revised upward for sales and all profit metrics. • Demand for TMP was stronger than expected due to robust semiconductor market conditions. • The impact from the situation in the Middle East is expected to be smaller than initially assumed. • Tescan will be consolidated from FY2026 Q3, with a six-month consolidation period. • FX assumptions have been revised to reflect a weaker yen. Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results • AMI: Analytical & Measuring Instruments, MED: Medical Systems, IM: Industrial Machinery, AE: Aircraft Equipment • AMI Key Models (LC: Liquid Chromatograph, MS: Mass Spectrometer System, GC: Gas Chromatograph) • TMP: Turbomolecular Pump

Page 3

Page 4

Consolidated Financial Performance 4 FX Impact (¥B) Sales OP +7.8 +1.7 FX gain/loss: +4.6 (Sales and OP are translated at average exchange rates, while FX gains and losses are recognized using period-end exchange rates.) FY2025 Q1 FY2026 Q1 FX loss: -1.3 FX gain: +3.4 Period-end rate: March 31 USD: ¥150 → ¥145 as of June 30 Period-end rate: March 31 USD: ¥160 → ¥162 as of June 30 *Figures are rounded to the nearest ¥0.1B and may not reconcile with the totals or differences shown. Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results Effective from FY2026 Q1, the Shimadzu Group has adopted OP before amortization of goodwill and other intangible assets as a key management performance indicator. For year-on-year comparison purposes, FY2025 Q1 has been restated to reclassify ¥0.4B of amortization of goodwill and other intangible assets. FY2025 FY2026 Changes % Net Sales 118.4 130.6 +12.2 +10% Operating Income 12.2 14.3 +2.1 +17% 　Operating Margin 10.3% 10.9% Ordinary Income 11.3 18.5 +7.2 +63% Profit Attributable to Owners of Parent 7.9 13.3 +5.4 +68% (Ref.) Operating Income Before Amortization of Goodwill and Other Intangible Assets 12.5 14.6 +2.1 +17% Average Rate: USD (Yen) 144.63 159.50 14.87 +10% Average Rate: Euro (Yen) 163.83 185.43 21.60 +13% R&D Expenses 7.3 7.0 -0.3 CAPEX 5.4 7.8 +2.5 Depreciation and Amortization 5.0 5.2 +0.2 Unit: ¥B YoY Business Results +0.6pt Q1 (Apr.-Jun.) Exchange Rates

Page 5

Consolidated OP Bridge 5 ◼ Sales: Higher sales and value-added pricing more than offset the impact of the situation in the Middle East. +3.4 ◼ Manufacturing: Improved production efficiency more than offset higher material costs. +0.1 ◼ Investments: Investments in DX and M&A-related expenses increased. -0.1 ◼ Higher Expenses: Outsourcing expenses as well as travel and transportation expenses increased. -1.2 Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results * Figures are rounded to the nearest ¥0.1B and may not reconcile with the totals or differences shown. +34 +1 ▲19 ▲12 +17 122 143 FY2025 1Q 営業面製造面成長投資・人財投資経費増為替影響 FY2026 1Q R&D expenses +0.3 Investments in DX -0.3 M&A-related expenses -0.1 Human capital investments -1.8 Improved production efficiency +0.8 Higher material costs -0.7 Impact of higher sales +1.7 Value-added pricing +1.7 (¥B) FY2025 Q1 +3.4 +0.1 -1.9 -1.2 +1.7 14.3 Sales Manufacturing Growth and Human Capital Investments Increase in Expenses FX Impact FY2026 Q1 Impact from the Situation in the Middle East: -1.5 12.2

Page 6

43.8 46.5 32.0 33.8 75.8 80.3 FY2025 FY2026 9.0 7.7 FY2025 FY2026 AMI / Sales and OP 6 ◼ Sales: Record-high Q1 sales for both Key Models and Other Models despite sales delays caused by the situation in the Middle East. Excluding FX, however, sales declined. ◼ OP: Declined due to higher material costs and sales delays caused by the situation in the Middle East. ◼ Impact from the Situation in the Middle East: Approximately ¥2.0B reduction in sales and approximately ¥1.5B reduction in OP. * Key Models： Liquid Chromatographs (LC), Mass Spectrometers (MS), and Gas Chromatographs (GC) Key Models Sales: ¥46.5B • LC sales increased in Japan, driven by pharmaceuticals, and in North America, driven by academia and government. • MS sales increased significantly in Europe but declined in India due to the situation in the Middle East. Other Models Sales: ¥33.8B • Sales declined in China and Southeast Asia due to the absence of large orders recorded a year earlier. Recurring Sales: ¥36.2B • Recurring revenue ratio: 45% (+3 percentage points YoY). • Consumables sales for the clinical market increased in Europe. (¥B) % indicates YoY changes. % indicates YoY changes. OP Before Amortization of Goodwill and Other Intangible AssetsSales Key Models Other Models +19% -15% +3% +2% +3% +6% +6% +6% Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results (+6% YoY) (+6% YoY) (+14% YoY) Effective from FY2026 Q1, the Shimadzu Group has adopted OP before amortization of goodwill and other intangible assets as a key management performance indicator. FY2025 figures have been restated to reclassify a total of ¥0.3B in amortization of goodwill and other intangible assets. (¥B) OPM 11.9％ OPM 9.6％

Page 7

AMI / Sales by Region 7 Unit: ¥B FY2025 FY2026 YoY Overview Changes Growth Japan 24.1 25.1 +1.0 +4% • LC sales increased, driven by the pharmaceutical market. • Sales of testing machines for the electrical and machinery industries increased. Overseas 51.7 55.2 +3.5 +7% • The overseas sales ratio increased from 68.2% to 68.8%. North America 9.2 10.3 +1.0 +11% • LC sales to academia and government increased. Europe 9.3 11.4 +2.1 +23% • MS sales increased for clinical testing laboratories, the food industry, and academia and government customers. China 16.7 17.0 +0.3 +2% • LC sales increased for biopharmaceutical applications. • Meanwhile, demand in the public sector, including the demand related to large-scale equipment renewal programs, remained weak and declined. Other Asian Countries (Excl. India) 7.4 6.9 -0.5 -6% • Although LC sales increased in Southeast Asia for pharmaceuticals, as well as academia and government, this was insufficient to offset the absence of large government orders recorded a year earlier. India 4.7 4.4 -0.3 -6% • LC and MS sales declined due to project delays caused by the situation in the Middle East. Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results

Page 8

9.5 13.4 4.2 3.5 13.7 16.9 FY2025 FY2026 -0.7 1.1 FY2025 FY2026 MED / Sales and OP 8 ◼ Sales: X-Ray System sales performed well globally, while Other Model sales declined following the scaling back sales of low-margin products. ◼ OP: Profitability improved significantly, driven by higher sales and contributions from new products. We will continue to focus on improving profitability. X-Ray Systems Sales: ¥13.4B • Solid performance driven by new Fluoroscopy Systems and Mobile X-Ray Systems. Other Models Sales: ¥3.5B • Declined due to the scaling back of low-margin products. Recurring Sales: ¥6.7B • Recurring revenue ratio: 39% (-8 percentage points YoY). • Recurring revenue increased mainly overseas; however, the ratio declined as product sales grew at a faster pace. X-Ray Systems Other Models-11% +6% -17% +23% -16% +41% - - Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results (+41% YoY) (-16% YoY) (+3% YoY) (¥B) % indicates YoY changes. % indicates YoY changes. Sales Effective from FY2026 Q1, the Shimadzu Group has adopted OP before amortization of goodwill and other intangible assets as a key management performance indicator. FY2025 figures have been restated to reclassify a total of ¥0.0B in amortization of goodwill and other intangible assets. OP Before Amortization of Goodwill and Other Intangible Assets OPM -5.2％ OPM 6.6％ (¥B)

Page 9

9.5 12.7 3.7 4.13.6 3.916.8 20.7 FY2025 FY2026 2.7 3.8 FY2025 FY2026 TMP Recurring IM / Sales and OP 9 ◼ Sales: TMP sales for semiconductor production equipment (SPE) increased significantly. ◼ OP: Increased significantly, driven by higher TMP sales. ◼ The negative impact initially anticipated from the situation in the Middle East did not materialize. Others TMP -0% +44% Sales: ¥12.7B Sales: ¥4.1B Sales: ¥3.9B • Sales for SPE applications increased significantly in Japan, Europe, Taiwan, and South Korea. • Sales for coating applications declined in China. • Service revenue from SPE applications increased. • Sales increased, mainly for industrial vehicles and construction machinery. • Industrial furnace sales declined. • TMP recurring revenue ratio: 21% (unchanged YoY) Sales: ¥2.7B Hydraulic Equipment +34% +12% +7% +3% -3% -19% TMP Others Hydraulic Equipment -4% +23% Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results (+34% YoY) (+35% YoY) (+12% YoY) (+7% YoY) Effective from FY2026 Q1, the Shimadzu Group has adopted OP before amortization of goodwill and other intangible assets as a key management performance indicator. FY2025 figures have been restated to reclassify a total of ¥0.0B in amortization of goodwill and other intangible assets. OPM 15.8％ OPM 18.4％ (¥B) % indicates YoY changes. % indicates YoY changes. Sales OP Before Amortization of Goodwill and Other Intangible Assets (¥B)

Page 10

7.6 8.3 2.3 2.7 9.9 11.0 FY2025 FY2026 2.1 2.7 FY2025 FY2026 AE / Sales and OP 10 ◼ Sales: Increased in both defense and commercial aircraft. ◼ OP: Increased significantly, driven by higher sales. Sales: ¥2.7B • Sales of onboard equipment for commercial aircraft and spare parts for airlines increased. • Continued to recover from supply chain disruptions. • Demand expanded in line with the Japanese government's policy to strengthen its defense capabilities. Sales: ¥8.3BDefense Commercial Aircraft +17% +10% +14% +11% +5% +17% Defense Commercial Aircraft +55% +34% Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results (+10% YoY) (+17% YoY) Effective from FY2026 Q1, the Shimadzu Group has adopted OP before amortization of goodwill and other intangible assets as a key management performance indicator. FY2025 figures have been restated to reclassify a total of ¥0.0B in amortization of goodwill and other intangible assets. OPM 20.7％ OPM 24.9％ (¥B) % indicates YoY changes. % indicates YoY changes. Sales OP Before Amortization of Goodwill and Other Intangible Assets (¥B)

Page 11

Page 12

FY2026 Full-Year Earnings Forecast Sales: -3.0 OP: -2.5Middle East- related Impact Full-Year FX Assumptions USD: ¥157.5 (H2 ¥155) EUR: ¥182.5 (H2 ¥180) ◼ Higher sales and value-added pricing are expected to more than offset the impact of the situation in the Middle East, resulting in higher sales and OP year on year. ◼ Compared with the initial forecast, higher sales and OP are expected, reflecting stronger-than-expected TMP demand, a smaller impact from the situation in the Middle East, a weaker yen, and the consolidation of Tescan. ◼ Tescan will be consolidated for six months. Sales: +16.5 OP Before Amortization of Goodwill and Other Intangible Assets: +2.8 Amortization of Goodwill and Other Intangible Assets: -3.8 Six-Month Consolidation of Tescan (Provisional Figure) 12Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results FY2026 New Forecast Changes % Changes % Net Sales 620.0 +59.3 +11% +45.0 +8% Operating Income 80.0 +6.3 +9% +4.0 +5% 　Operating Margin 12.9% Ordinary Income 81.0 -1.8 -2% +6.0 +8% Profit Attributable to Owners of Parent 59.0 -1.5 -2% +4.0 +7% (Ref.) Operating Income Before Amortization of Goodwill and Other Intangible Assets 85.0 +9.9 +13% +7.8 +10% YoY Business Results -0.2pt Units: ¥B vs. Initial Forecast -0.3pt YoY vs. Initial Forecast YoY vs. Initial Forecast YoY vs. Initial Forecast 32.0 +2.9 +1.5 30.0 +7.9 +5.0 20.0 -0.4 ― Depreciation and AmortizationCAPEXR&D Expenses (¥B) (¥B) (¥B)(¥B)(¥B)

Page 13

Consolidated OP Bridge – FY2026 Forecast Revision ◼ Sales: Higher sales and value-added pricing are expected to increase OP. ◼ Manufacturing: Continued increases in material costs are expected to outweigh production efficiency gains, reducing OP. ◼ Investments: Growth investments in R&D and DX as well as human capital investments are expected to increase. The forecast also includes ¥1.1B in M&A-related expenses. ◼ The forecast incorporates Tescan’s earnings and amortization of goodwill and other intangible assets, while favorable FX effects are expected to contribute positively. 13Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results +194 ▲23 ▲135 +12 ▲10 +25 737 800 FY2025 営業面製造面成長投資・人財投資経費減 Tescan連結影響為替影響 FY2026 -2.3 Impact from the Situation in the Middle East: -2.5 (+1.5 vs. initial forecast) 73.7 +19.4 -13.5 +1.2 -1.0 +2.5 80.0 FY2025 Sales Manufacturing Growth and Human Capital Investments Decrease in Expenses FX Impact FY2026Consolidation of Tescan R&D expenses -1.4 Investments in DX, etc. -3.5 M&A-related expenses -1.1 Human capital investments -7.5 Improved production efficiency +3.7 Higher material costs -6.0 (-1.5 vs. initial forecast) Impact of higher sales +10.4 (+4.9 vs. initial forecast) Value-added pricing +9.0 OP +2.8 (including Tescan’s R&D expenses -1.5) Amortization of goodwill and other intangible assets -3.8 (¥B) * Figures are rounded to the nearest ¥0.1B and may not reconcile with the totals or differences shown.

Page 14

FY2026 Full-Year Segment Forecasts We aim to outperform our targets by accelerating sales of new products and optimizing pricing. ◼ AMI: Higher sales and OP driven by new product expansion, deeper penetration of solid markets, and recurring revenue growth. ◼ MED: Improve profitability by expanding differentiated products, optimizing the product portfolio, and strengthening the recurring business. ◼ IM: Achieve higher sales and OP by capturing robust TMP demand from the semiconductor market and expanding recurring revenue. ◼ AE: Deliver business growth, supported by favorable FX effects and robust demand. 14Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results Effective from FY2026 Q1, the Shimadzu Group has adopted OP before amortization of goodwill and other intangible assets as a key management performance indicator. FY2025 figures have been restated to reclassify a total of ¥1.4B in amortization of goodwill and other intangible assets. YoY Changes % Changes % Changes AMI 364.9 410.0 +45.1 +12% 53.8 63.0 +9.2 +17% 14.7% 15.4% +0.6pt MED 73.8 71.5 -2.3 -3% 5.0 6.0 +1.0 +19% 6.8% 8.4% +1.6pt IM 71.5 86.0 +14.5 +20% 10.7 16.0 +5.3 +50% 14.9% 18.6% +3.7pt AE 43.4 47.0 +3.6 +8% 8.2 6.0 -2.2 -27% 19.0% 12.8% -6.2pt Other 7.1 5.5 -1.6 -23% 1.2 1.5 +0.3 +27% 12.4% 20.5% +8.1pt Adjustments — — — — -3.7 -7.5 -3.8 — — — — Total 560.7 620.0 +59.3 +11% 75.1 85.0 +9.9 +13% 13.4% 13.7% +0.3pt Units: ¥B FY2025 YoY FY2025FY2025 YoYFY2026 New Forecast FY2026 New Forecast OPMOP Before Amortization of Goodwill and Other Intangible AssetsNet Sales FY2026 New Forecast

Page 15

Topics: Revision to Full-Year Guidance ◼ Impact of the Consolidation of Tescan ◼ Outlook for the Impact of the Situation in the Middle East ◼ AMI / Regional Sales Outlook ◼ AMI / Progress in Value-Added Pricing 15Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results Topics Revision to Full-Year Guidance

Page 16

vs. Initial Forecast Changes % Changes % Changes AMI 364.9 385.0 410.0 +25.0 +6% 53.8 62.6 63.0 +0.4 +1% 14.7% 16.3% 15.4% -0.9pt MED 73.8 70.0 71.5 +1.5 +2% 5.0 5.6 6.0 +0.4 +7% 6.8% 8.0% 8.4% +0.4pt IM 71.5 70.5 86.0 +15.5 +22% 10.7 10.0 16.0 +6.0 +60% 14.9% 14.2% 18.6% +4.4pt AE 43.4 44.0 47.0 +3.0 +7% 8.2 5.0 6.0 +1.0 +20% 19.0% 11.4% 12.8% +1.4pt Other 7.1 5.5 5.5 +0.0 0% 1.2 1.5 1.5 +0.0 0% 12.4% 20.5% 20.5% +0.0pt Adjustments — — — — — -3.7 -7.5 -7.5 +0.0 — — — — — Total 560.7 575.0 620.0 +45.0 +8% 75.1 77.2 85.0 +7.8 +10% 13.4% 13.4% 13.7% +0.3pt FY2026 New Forecast OPMOP Before Amortization of Goodwill and Other Intangible AssetsNet Sales vs. Initial ForecastFY2026 New Forecast FY2025 FY2026 Initial Forecast FY2025 FY2026 Initial Forecast vs. Initial ForecastFY2026 New Forecast FY2025 FY2026 Initial Forecast Units: ¥B FY2026 Full-Year Segment Forecasts Sales and OP forecasts have been revised upward for all segments. Amortization of goodwill and other intangible assets is excluded from segment OP. ◼ AMI: Sales and OP forecasts have been revised upward, reflecting favorable FX effects and the consolidation of Tescan, despite the impact of the situation in the Middle East. ◼ MED: Sales and OP forecasts have been revised upward, reflecting favorable FX effects. ◼ IM: Sales and OP forecasts have been revised upward, reflecting robust TMP market conditions, a smaller impact from the situation in the Middle East, and favorable FX effects. ◼ AE: Sales and OP forecasts have been revised upward, supported by favorable FX effects and robust demand. 16Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results Effective from FY2026 Q1, the Shimadzu Group has adopted OP before amortization of goodwill and other intangible assets as a key management performance indicator. FY2025 figures have been restated to reclassify a total of ¥1.4B in amortization of goodwill and other intangible assets.

Page 17

Impact of the Consolidation of Tescan ◼ Market Environment ・ Semiconductor-related markets remain robust. Advances in miniaturization and 3D integration are expected to drive market growth for laser processing systems and electron microscopes. ・ SEM adoption is also expanding in the life sciences market. ◼ Recent Order Trends ・ Received orders for multiple systems from semiconductor manufacturers for R&D applications. ・ Cross-selling initiatives have begun, primarily in Asia. ◼ Tescan’s Standalone Outlook for Fiscal Year Ending December 2026 ・ Orders and sales are both expected to increase at a double-digit rate from the FY2025 levels*1. ・ EBITDA is also expected to grow at a double-digit rate from the FY2025 level*2. *1. USD 208 million in orders and USD 193 million in sales *2. USD 40 million ◼ Tescan will be consolidated into the AMI segment from FY2026 H2. The AMI forecast incorporates ¥16.5B in sales and ¥2.8B in OP before amortization of goodwill and other intangible assets. On the other hand, ¥1.1B in M&A-related expenses is recognized at the corporate level. ◼ At the consolidated level, OP has been reduced by ¥3.8B to reflect provisional amortization of goodwill and other intangible assets arising from the acquisition of Tescan. 17Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results

Page 18

Outlook for the Impact of the Situation in the Middle East ◼ Although the situation in the Middle East has persisted longer than initially assumed (a resolution within three months), thefull-year negative impact is now expected to be ¥7.0B smaller for sales and ¥1.5B smaller for OP. ◼ Primary Impacts (1) Lower sales due to market slowdown (Indirect Impact) Sales: -¥3.0B OP: -¥2.0B (2) Higher oil prices and logistics costs (Direct Impact) OP: -¥3.0B ◼ We plan to offset higher costs through cost reductions and pricing actions. Unit: ¥B Primary Impact Initial Impact Assumption (YoY) Updated Impact Assumption (YoY) Improvement from Initial Assumption (1) Lower Sales Due to Market Slowdown (Indirect Impact) Sales: -10.0 OP: -5.5 Sales: -3.0 OP: -2.0 Impact remains in Japan, Southeast Asia, and India in AMI. Sales: +7.0 OP: +3.5 Concerns over a global market slowdown have eased. (2) Higher Costs (Direct Impact) OP: -1.5 OP: -3.0 OP: -1.5 Material and logistics costs are expected to remain elevated. (3) Others OP: +3.0 Cost controls and pricing actions. OP: +2.5 OP: -0.5 Total Sales: -10.0 OP: -4.0 AMI (Sales: -6.0, OP: -2.5) MED (Sales: -0.5, OP: limited) IM (Sales: -3.5, OP: -1.5) Sales: -3.0 OP: -2.5 AMI (Sales: -2.5, OP: -2.5) MED (Sales: -0.5, OP: limited) Sales: +7.0 OP: +1.5 AMI (Sales: +3.5, OP: unchanged) IM (Sales: +3.5, OP: +1.5) 18Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results

Page 19

Region Q1 Outlook Japan • Business remained solid despite the impact of the situation in the Middle East. • Demand supported by supplementary government budgets for academia and government is expected to accelerate from Q3 onward. • Expected contribution from new products • Tescan consolidation effect North America • Market conditions remained challenging, with demand for Nexera QX moderating following last year’s solid growth. • Recovery in the clinical testing market is expected. Europe • Growth was driven by the clinical market as well as academia and government. • Further growth is expected in the food and pharmaceutical markets, in addition to the clinical as well as academia and government markets. China • Recovery in private-sector demand remained slow, while large-scale equipment renewal programs continued to lack momentum. • Growth is expected in biopharmaceutical applications and China RoHS-related markets. India • The impact from the situation in the Middle East was more severe than initially expected. • Although local currency weakness may weigh on purchasing power, capital investment appetite remains solid and a recovery is expected. AMI / Regional Sales Outlook YoY FY2026 Outlook (w/o FX) Japan 10-13% North America 7-9% Europe 7-9% China 7-9% Other Asian Countries 7-9% Of which: India 7-9% AMI 7-9% 19Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results

Page 20

AMI / Progress in Value-Added Pricing ◼ Gross profit margin improved significantly by value -added pricing mainly for new products and enhanced production efficiency. ◼ During the Medium -Term Management Plan period starting in FY2026 , we will further improve gross margin by implementing and accelerating new and existing initiatives. ◼ We will focus on strengthening earning power while working to control expenses. Existing Initiatives • Improving the sales mix • Enhancing production efficiency A New Initiative Launched in FY2026 • Optimizing pricing across both existing and new products 20Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results FY2024 100 FY2025 101 FY2026 Q1 105 Gross Margin Trend Indexed to FY2024 Full-Year = 100

Page 21

Notice: AMI Business Briefing & Shimadzu Booth Tour at JASIS (Sept. 4) 21 Date / Time September 4, 2026 (Fri.) 13:00–15:45 Agenda 13:00–13:50 Presentation: Initiatives for the Life Sciences and Semiconductor Markets 13:50–14:30 Q&A 14:45–15:45 Shimadzu Booth Tour at JASIS * Note: The entire session, including the booth tour, will be conducted in Japanese. Presenters Masami Tomita Managing Executive Officer General Manager of Analytical & Measuring Instruments Division Tairo Ogura Deputy General Manager of Analytical & Measuring Instruments Division General Manager of Life Science Business Department, Analytical & Measuring Instruments Division Haruhiko Miyagawa Deputy General Manager of Analytical & Measuring Instruments Division Chairman of the Board, TESCAN GROUP, a.s. Venue Makuhari Messe and Live Online Streaming ◼ Shimadzu will host an AMI Business Briefing for analysts and institutional investors at JASIS, one of Asia’s largest exhibitions for analytical and scientific instruments. Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results

Page 22

Excellence in Science ＆ Best for Our Customers Contact Contact: Investor Relations Group Corporate Communication Department Shimadzu Corporation Email: ir@group.shimadzu.co.jp Forward-looking statements in this presentation may differ materially from actual results due to various external factors, including economic conditions, foreign exchange fluctuations, and technological developments.

Page 23

Page 24

Segment Performance 24 Segment OP is now presented as OP before amortization of goodwill and other intangible assets, a metric that better reflects underlying earning power. ◼ AMI: Higher sales, lower OP; record-high sales. ◼ MED: Higher sales and OP; record-high sales and OP, with improved profitability. ◼ IM: Higher sales and OP; record-high sales and OP. ◼ AE: Higher sales and OP; record-high sales and OP. Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results Effective from FY2026 Q1, the Shimadzu Group has adopted OP before amortization of goodwill and other intangible assets as a key management performance indicator. FY2025 figures have been restated to reclassify a total of ¥0.4B in amortization of goodwill and other intangible assets. YoY Changes % Changes % Changes AMI 75.8 80.3 +4.5 +6% 9.0 7.7 -1.4 -15% 11.9% 9.6% -2.4pt MED 13.7 16.9 +3.2 +23% -0.7 1.1 +1.8 — -5.2% 6.6% +11.8pt IM 16.8 20.7 +3.9 +23% 2.7 3.8 +1.2 +44% 15.8% 18.4% +2.6pt AE 9.9 11.0 +1.1 +11% 2.1 2.7 +0.7 +34% 20.7% 24.9% +4.2pt Other 2.2 1.6 -0.5 -25% 0.2 0.1 -0.1 — 8.8% 6.7% -2.1pt Adjustments — — — — -0.7 -0.9 -0.1 — — — — Total 118.4 130.6 +12.2 +10% 12.5 14.6 +2.1 +17% 10.6% 11.2% +0.6pt OP Before Amortization of Goodwill and Other Intangible Assets Operating Margin YoYFY2025 FY2025FY2026 Net Sales YoYFY2025 FY2026 FY2026 Units: Billions of yen

Page 25

AMI / Sales Mix in Q1 25 Sales Mix by Model Outer Ring: FY2026 Results / Inner Ring: FY2025 Results Sales Mix by Region Outer Ring: FY2026 Results / Inner Ring: FY2025 Results 32% 12% 12% 22% 10% 6% 6% Japan 31% North America 13% Europe 14% China 21% Other Asian Countries (Excluding India) 9% India 5% Other Countries 7% 57%43% Key Models 57% Other 43% Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results

Page 26

37% 19% 18% 26% Healthcare 37% Industry (Green and Material) 20% Academia/ Government 14% Other 29% AMI / Sales Mix by Market in Q1 26 Outer Ring: FY2026 Results / Inner Ring: FY2025 Results Sales Mix by Market Markets and Key Industries Sales Mix Sales Overview FY2025 FY2026 YoY Healthcare 37% 37% +4% • Pharmaceutical demand declined in India but increased in Japan and China. • Clinical (medical institutions) demand increased in Europe. • Pharmaceuticals & Food • Medical Institutions • Contract Testing Laboratories Industry (Green & Materials) 19% 20% +15% • Demand from the transportation and chemical industries declined in Japan due to concerns related to the situation in the Middle East. • Demand in China continued to recover from the slowdown seen in previous years. • Chemicals & Materials • Electronics • Automotive Academia & Government 18% 14% -15% • China and Southeast Asia were affected by the absence of large orders recorded a year earlier. • Business remained solid in Japan and Europe. Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results

Page 27

AMI / YoY Sales Growth of Key Models 27 * Key Models： Liquid Chromatographs (LC), Mass Spectrometers (MS), and Gas Chromatographs (GC) ◼ LC: Increased in Japan driven by pharmaceuticals, while sales declined in India due to the situation in the Middle East. ◼ MS: Increased in Europe, driven by the clinical market, while sales declined in India due to the situation in the Middle East. ◼ GC: Declined in Japan and North America due to the impact of the situation in the Middle East. Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Key Models +3% -2% +2% +8% +3% +3% +5% +7% +10% +7% +6% All +3% -1% +4% +4% +3% +3% +6% +5% +5% +5% +6% Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Key Models -6% -5% -0% +6% -1% +9% +6% +5% +6% +6% -3% All -5% -3% +3% +3% -0% +7% +7% +3% +2% +5% -1% w/o FX with FX FY2026 FY2026FY2024 FY2025 FY2024 FY2025

Page 28

AMI / YoY Sales Growth by Region 28 ◼ Japan: LC sales increased in pharmaceuticals, while testing machines grew in the electronics and machinery sectors. ◼ Overseas: MS sales increased in Europe driven by the clinical market, while LC and MS sales declined in Southeast Asia and India due to the situation in the Middle East. Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Japan +5% +2% +12% -2% +3% +4% +11% +3% +4% +5% +4% North America +13% +13% +21% +11% +14% +13% +4% +10% +8% +8% +11% Europe +8% +4% +3% +7% +5% +2% +13% +17% +14% +12% +23% China -5% -19% -10% -2% -9% -8% -1% +1% +5% -1% +2% Other Asian Countries +4% +3% +1% +13% +5% +13% +5% +0% +14% +8% -6% India +20% +25% +4% +24% +17% +16% -1% -5% +25% +8% -6% Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Japan +5% +2% +12% -2% +3% +4% +11% +3% +4% +5% +4% North America -0% +9% +17% +7% +8% +22% +5% +9% +5% +9% +1% Europe -4% -0% +0% +7% +1% +4% +9% +8% +1% +5% +9% China -16% -21% -12% -4% -14% -1% +1% +0% +2% +0% -7% Other Asian Countries -7% -0% -1% +12% +1% +21% +7% +0% +12% +9% -14% India +6% +20% +0% +21% +11% +25% +0% -6% +23% +10% -15% FY2026 FY2026FY2025w/o FX FY2024 FY2025FY2024with FX * India is included in Other Asian Countries.

Page 29

AMI / YoY Sales Growth by Market 29 * Including FX Impact Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Healthcare +1% -4% +5% +11% +3% +2% +7% -3% -3% +1% +4% Industry (Green and Material) +7% +2% +2% +8% +5% -6% +1% +0% +3% +3% +15% Academia/ Government -2% -8% -8% -7% -6% +9% -1% +14% +7% +7% -15% FY2026FY2024 FY2025

Page 30

MED / Sales Mix in Q1 30 Sales Mix by Model Outer Ring: FY2026 Results / Inner Ring: FY2025 Results Sales Mix by Region Outer Ring: FY2026 Results / Inner Ring: FY2025 Results 69% 31% X-Ray Systems 79% Other 21% 51% 17% 3% 6% 11% 12% Japan 40% North America 20% Europe 6% China 8% Other Asian Countries 12% Other Countries 14% Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results

Page 31

MED / Sales by Region 31 Unit: ¥B FY2025 FY2026 YoY Overview Changes Growth Japan 7.0 6.8 -0.3 -4% • X-Ray System sales increased overall. • Other Model sales declined due to the absence of large orders recorded a year earlier. Overseas 6.6 10.1 +3.5 +52% • The overseas sales ratio increased to 60%, up 11 percentage points YoY . North America 2.3 3.3 +1.0 +42% • Radiography System sales and Mobile X-Ray System sales grew on the back of contributions from new products. Europe 0.4 1.0 +0.6 +169% • Radiography System sales and Mobile X-Ray System sales grew on the back of contributions from new products. China 0.9 1.4 +0.5 +63% • Demand recovered under the government’s stimulus package, driving growth in Radiography System and Fluoroscopy System sales. Other Asian Countries 1.4 2.1 +0.6 +44% • Angiography System sales recorded solid growth in Southeast Asia, a strategic focus market. Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results

Page 32

Recurring Revenue Ratio 32 * Excluding FX Impact ◼ AMI: Sales of consumables and maintenance services for the clinical market increased in Europe. ◼ MED: Maintenance and service revenue increased, mainly overseas, supported by an expanded service network. ◼ TMP: Recurring revenue increased in Japan, China, Taiwan, and South Korea as customer coverage expanded. Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Recurring Sales YoY +0% +4% +10% +7% +6% +10% +6% +5% +7% +7% +7% Recurring Ratio 41% 38% 40% 35% 38% 42% 38% 41% 37% 39% 45% Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Recurring Sales YoY -1% +0% -0% +4% +1% +6% +5% +5% -1% +3% -3% Recurring Ratio 41% 36% 40% 34% 37% 47% 35% 37% 35% 38% 39% Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Recurring Sales YoY +46% +50% +34% +28% +38% +24% +23% +29% +32% +27% +27% Recurring Ratio 19% 19% 22% 19% 20% 21% 25% 25% 26% 24% 21% FY2026 FY2026 FY2026FY2024 FY2025 FY2024 FY2025 FY2024 FY2025 TMP MED AMI

Page 33

Consolidated Balance Sheet 33 ◼ Total assets as of June 30, 2026: ¥730.5B, down ¥7.5B from March 31, 2026. ◼ Current assets decreased primarily due to the collection of trade receivables. Current Assets -20.0 Current Liabilities -18.4 Net Assets +10.0 Assets Liabilities and Net Assets Income taxes payable -10.6 (¥B) Changes are compared with March 31, 2026. Valuation difference on available-for-sale securities +6.6Total Assets 730.5 Total Liabilities and Net Assets 730.5 Trade receivables -18.9 Provision for bonuses -8.2 Investments and Other Assets 104.3 (+10.8) Intangible Assets 24.1 (+0.2) Property, Plant and Equipment 124.3 (+1.5) Current Assets 477.8 (-20.0) Net Assets 575.2 (+10.0) Non-Current Liabilities 23.5 (+0.9) Current Liabilities 131.8 (-18.4) Copyright © Shimadzu Corporation. All Rights Reserved. | FY2026 Q1 Results

Slides